Clinical Trial Update: Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating different doses and dosing regimens of subcutaneous secukinumab (AIN457) in adults with moderate-to-severe chronic plaque psoriasis; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate to Severe Plaque-type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2015-05-19